title: B-cell-depleting induction therapy and acute cellular rejection.
authors.forename: Menna R
authors.initials: MR
authors.lastname: Clatworthy
authors.forename: Christopher J E
authors.initials: CJ
authors.lastname: Watson
authors.forename: Gemma
authors.initials: G
authors.lastname: Plotnek
authors.forename: Vicky
authors.initials: V
authors.lastname: Bardsley
authors.forename: Afzal N
authors.initials: AN
authors.lastname: Chaudhry
authors.forename: J Andrew
authors.initials: JA
authors.lastname: Bradley
authors.forename: Kenneth G C
authors.initials: KG
authors.lastname: Smith
mesh_terms: D000208:Acute Disease; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D001402:B-Lymphocytes; D016207:Cytokines / Q000097:blood; D000077561:Daclizumab; D006084:Graft Rejection / Q000276:immunology*; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D053208:Kaplan-Meier Estimate; D016030:Kidney Transplantation / Q000276:immunology*; D018655:Lymphocyte Count; D008212:Lymphocyte Depletion; D000069283:Rituximab; D019172:Transplantation Conditioning; D014181:Transplantation Immunology
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D016207:Cytokines; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D000069283:Rituximab; D000077561:Daclizumab